An Autopsy Case of Misdiagnosed Wernicke’s Syndrome after Intragastric Balloon Therapy

Paola Vellante, Aldo Carnevale, and Cristian D’Ovidio

Department of Medicine and Aging Sciences, Università degli Studi “G. d’Annunzio”, Via Dei Vestini, 66100 Chieti, Italy

Correspondence should be addressed to Paola Vellante; paola.vellante@gmail.com

Received 21 September 2017; Revised 6 January 2018; Accepted 21 January 2018; Published 13 February 2018

1. Introduction

Obesity is a growing health problem, and once lifestyle modifications and pharmacotherapies have failed, intragastric balloon (IGB) therapy represents a safe and effective treatment that can be considered before bariatric surgery techniques. IGB therapy is indicated for patients whose body mass index (BMI) is from 30 kg/m² to 40 kg/m², to prepare these superobese patients for bariatric surgery. It also represents a temporary treatment of choice. Nowadays, thousands of IGBs are placed globally, due to their versatility, low invasiveness, and safety.

Intragastric balloon placement is a minimally invasive procedure that was first performed in the early 1980s, and it has become popular in Europe only in recent years [1]. The use of IGB therapy has spread easily, such that the US Food and Drug Administration is going to approve more types of IGBs [2]. Of note, to correctly manage IGB therapy, an interdisciplinary approach is recommended, with the patients enrolled in a medically supervised weight-loss program.

There have been few reported cases of Wernicke’s syndrome related to IGB therapy [3, 4]. In these cases, the diagnosis of Wernicke’s syndrome was made in its early stages and was immediately treated. In contrast, there are no reports of late Wernicke’s syndrome diagnosis (i.e., after IGB therapy) in the international literature.

The aim of this case report is to draw attention to the possible onset of Wernicke’s syndrome during IGB therapy. Patients should be informed that Wernicke’s syndrome can be a side effect of IGB therapy.

2. Case Report

We present here an autopsy case of a 51-year-old woman who underwent IGB therapy. At the time of the IGB placement, her BMI was 46.48 kg/m². Six months later, her BMI had decreased to 30.5 kg/m². Due to the lack of follow-up reports, it is unknown whether the patient missed any control visits or whether she was adequately followed up.

Seven months after the IGB placement, the patient arrived at the Emergency Unit complaining of fever, cough, lower limb asthenia, and general malaise. She was diagnosed with bronchial pneumonitis, and antibiotic therapy was prescribed. The patient was then discharged and sent to be followed up by her general practitioner. The IGB was removed
1 month later (i.e., it remained in situ for 8 months since its placement).

After a week, the patient was admitted to the hospital for asthenia, memory deficit, and progressive worsening of her general malaise. During this hospitalization, her relatives reported a history of vomiting that was correlated with food intake and that had started soon after the IGB placement. It then appeared to worsen from the fourth month after the IGB placement. Moreover, the relatives reported a diagnosis of relatively unspecified peripheral neuropathy.

The patient then contracted severe nosocomial pneumonia, and she soon progressed into septic shock. After an episode of cardiac arrest, the patient was transferred to the Intensive Care Unit, while in a coma.

The laboratory examinations during the hospitalization of this patient revealed dysproteinemia, with total protein of 4.6 g/dL (normal range: 6.6–8.7 g/dL) and albumin of 21.4 g/L (normal range: 35–52 g/L). Her serum thiamine was never determined, although thiamine was administered since the date of her cardiac arrest. After this episode, cerebral computed tomography showed hypodensity, edema, and vascular problems in the cerebellum vermal and encephalic trunk, and on the basis of the patient history, a consultant neurologist hypothesized Wernicke's syndrome at the origin of her illness. Eight days later, the patient was declared brain death.

The laboratory examinations during the hospitalization of this patient revealed dysproteinemia, with total protein of 4.6 g/dL (normal range: 6.6–8.7 g/dL) and albumin of 21.4 g/L (normal range: 35–52 g/L). Her serum thiamine was never determined, although thiamine was administered since the date of her cardiac arrest. After this episode, cerebral computed tomography showed hypodensity, edema, and vascular problems in the cerebellum vermal and encephalic trunk, and on the basis of the patient history, a consultant neurologist hypothesized Wernicke's syndrome at the origin of her illness. Eight days later, the patient was declared brain death.

The following fatal sequence can be hypothesized. The IGB therapy appears to have caused persistent vomiting, which was generally ignored by the patient herself possibly due to her not well defined eating disorder with no specific cause. However, there are no comprehensive medical reports available. As the neurologist hypothesized, these events appear to have led to thiamine deficiency, which appeared initially as neuropathy and progressive immobility and then as Wernicke's syndrome. The immobility of the patient had a major role in her impaired pulmonary ventilation, which led to serious pneumonia. Finally, cardiac arrest while in septic shock caused a pontocerebellar infarction and brain death.

3. Discussion

The mechanism by which IGB induces weight loss is not fully understood [5]. It is believed that IGB reduces the gastric reservoir, leading to early and prolonged satiety and delayed gastric emptying. This would stimulate the gastric baroreceptors and also regulate hormone-mediated signal transduction [6]. On the contrary, IGBs would have no direct effects on nutrient absorption and metabolism.

Generally, the IGB is removed after 6 months, regardless of the BMI reached by the patient [7]. In cases of intolerance, the IGB can be removed earlier [8]. However, prolonged IGB therapy up to 14 months has been reported to maintain satiety and improve weight loss, without any safety issues [9].

In the present case, the IGB therapy duration of 8 months cannot be considered as the direct and only cause of Wernicke's syndrome, due to the lack of follow-up data. According to the literature data, persistent vomiting can be considered as the main cause of Wernicke's syndrome in this case. Nevertheless, Wernicke's syndrome has rarely been related to IGB therapy [3, 4].

The more common side effects of IGB therapy occur at relatively high rates, but most of these are self-limiting [6]. They are mainly accommodative in nature (i.e., nausea, abdominal pain, vomiting, and dyspepsia), and they generally decrease in frequency over time. Severe acid reflux can exacerbate the situation in ≤7% of patients. Major complications during IGB therapy occur in ≤2% of patients, and these include gastrointestinal ulceration, dehydration, luminal obstruction, and perforation [10]. There are also reports of fatal complications following IGB therapy, although none of these have been correlated to Wernicke's syndrome [11–13].

Wernicke's syndrome is the acute phase of thiamine (i.e., vitamin B1) deficiency, and it is characterized by mental confusion, ophthalmoplegia/nystagmus, and ataxia. Then, Korsakoff's syndrome is the chronic phase of thiamine deficiency, and it consists of antegrade and retrograde amnesia, disorientation, confabulation, and limited insight. In addition to damage to the central nervous system, thiamine deficiency can cause peripheral injury (polyneuropathy), and it can have a wide range of severity [14–16].

Prior to the first years of the 2000s [17], Wernicke-Korsakoff syndrome and neuropathy were rarely observed, except mainly in patients who received unbalanced diets or were undergoing rapid weight loss. Only one case was referred to IGB therapy. All such cases were characterized by severe vomiting, which interfered with the intake of food and vitamin supplements. This resulted in severe neurologic manifestations, which mostly affected the lower limbs. All of these patients recovered after vitamin B1 replenishment and without significant sequela. So, there is a need for a high degree of clinical awareness, with urgent therapeutic intervention required when thiamine deficiency is suspected or is diagnosed.

In more recent years [15], some 50 cases of neurologic symptoms after bariatric procedures have been reported. These cases presented as both peripheral neuropathy (62%) and encephalopathy (31%). Koffman et al. [15] recommended routine monitoring of micronutrient levels and the possibility of neurological complications where there are neurological symptoms after bariatric surgery.

A recent review [4] on Wernicke's syndrome concluded that there is a lack of sufficient data on micronutrient deficiency after restrictive weight-loss interventions (e.g., as for IGB therapy) and that persistent vomiting can be considered as the major determinant of Wernicke's syndrome. This thus leads to impairment of thiamine absorption and, in turn, to thiamine deficiency. However, the duration of such vomiting varies widely among patients, and thus it has not been possible to define a cut-off limit for the onset of Wernicke's syndrome.
Current guidelines do not recommend micronutrient supplementation for all patients undergoing restrictive weight-loss interventions (including for IGB therapy). There is thus a great need for prospective studies to evaluate changes in micronutrients levels under the different types of surgery. Strict monitoring of these patients is needed, because untreated thiamine deficiency can cause serious, and potentially irreversible, neurological damage, or death. Although thiamine deficiency is much more frequent in patients who undergo duodenum and jejunum bypasses (i.e., the preferred absorption sites), patients who undergo IGB therapy are also at an increased risk of thiamine deficiency. During IGB therapy, thiamine deficiency can be the result of restricted nutrient intake, persistent vomiting, and the common noncompliance with vitamin and mineral supplementation.

The treatment of Wernicke’s syndrome should begin at the first medical examination, when physicians are responsible for making patients aware that they should not ignore episodes of vomiting (i.e., they should not be accepted, not even to achieve greater weight loss) and aware of the importance of an equilibrated diet. Physicians must also be aware that some eating disorders can appear after bariatric procedures [18]. The patients need to be involved in all of the decisions made, and they must accept the full medically supervised weight-loss program as part of their IGB therapy.

4. Conclusions

Although the international literature mainly stresses the possibility of weight regain after IGB therapy [19] and the correlation between weight loss and reduction of obesity-related complications [12], the case presented here shows that IGB therapy must be approached as a multidisciplinary medical program and that patients must be well informed of all of the possible side effects. It is now mandatory to report and carefully investigate any neurological signs that appear during IGB therapy, or after IGB removal. Indeed, the clinical expression of thiamine deficiency (i.e., from neuropathy to encephalopathy) is reversible if diagnosed and treated early.

Disclosure

This study did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

The authors have no conflicts of interest to declare regarding this study.

References

[1] J. J. Gleysteen, “A history of intragastric balloons,” Surgery for Obesity and Related Diseases, vol. 12, no. 2, pp. 430–435, 2016.
[2] “U. S. Food and Drug Administration,” 2017, http://www.fda.gov/MedicalDevices.
[3] M. Milone, V. Scarano, M. N. D. Di Minno, R. Lupoli, F. Milone, and M. Musella, “Rapid onset of Wernicke syndrome after gastric balloon positioning,” European Journal of Clinical Nutrition, vol. 66, no. 8, p. 971, 2012.
[4] M. Milone, M. N. D. Di Minno, R. Lupoli et al., “Wernicke encephalopathy in subjects undergoing restrictive weight loss surgery: A systematic review of literature data,” European Eating Disorders Review, vol. 22, no. 4, pp. 223–229, 2014.
[5] J. T. Evans and M. H. Delegge, “Review: Intragastric balloon therapy in the management of obesity: Why the bad wrap?” Journal of Parenteral and Enteral Nutrition, vol. 35, no. 1, pp. 25–31, 2011.
[6] Y. Zheng, M. Wang, S. He, and G. Ji, “Short-term effects of intragastric balloon in association with conservative therapy on weight loss: A meta-analysis,” Journal of Translational Medicine, vol. 13, no. 1, article no. 246, 2015.
[7] M. P. Charalambous, J. Thompson, and E. Efthimiou, “Late gastric perforation after insertion of intragastric balloon for weight loss; video case report and literature review,” Surgery for Obesity and Related Diseases, vol. 8, no. 1, pp. 121–123, 2012.
[8] N. Kumar, F. Bazerbachi, T. Rustagi et al., “The Influence of the Orbera Intragastric Balloon Filling Volumes on Weight Loss, Tolerability, and Adverse Events: a Systematic Review and Meta-Analysis,” Obesity Surgery, vol. 27, no. 9, pp. 2272–2278, 2017.
[9] G. Alfredo, M. Roberta, F. Francesca et al., “Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months,” Surgical Endoscopy, vol. 29, no. 8, pp. 2339–2343, 2015.
[10] P. Laing, T. Pham, L. J. Taylor, and J. Fang, “Filling the Void: A Review of Intragastric Balloons for Obesity,” Digestive Diseases and Sciences, vol. 62, no. 6, pp. 1399–1408, 2017.
[11] C. Spyropoulous, E. Katsakoulis, N. Mead, K. Vagenas, and F. Kalfarentzos, “Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy,” Surgery for Obesity and Related Diseases, vol. 3, no. 1, pp. 78–83, 2007.
[12] A. Escudero Sanchis, I. Catalán Serra, J. Gonzalvo Sorribes et al., “Effectiveness, safety and tolerability of intragastric balloon in association with low-calorie diet for the treatment of obese patients,” Revista Española de Enfermedades Digestivas, vol. 100, no. 6, pp. 349–354, 2008.
[13] M. Ballaré, M. Orsello, and M. Del Piano, “A case of death after insertion of an intragastric balloon for treatment of morbid obesity,” Digestive and Liver Disease, vol. 36, no. 7, p. 499, 2004.
[14] J. R. Berger, “The neurological complications of bariatric surgery,” JAMA Neurology, vol. 61, no. 8, pp. 1185–1189, 2004.
[15] B. M. Koffman, L. J. Greenfield, I. I. Ali, and N. A. Pirzada, “Neurologic complications after surgery for obesity,” Muscle & Nerve, vol. 33, no. 2, pp. 166–176, 2006.
[16] M. E. Mason, H. Jalagani, and A. I. Vinik, “Metabolic complications of bariatric surgery: Diagnosis and management issues,” Gastroenterology Clinics of North America, vol. 34, no. 1, pp. 25–33, 2005.
[17] L. Claudio Lopes Chaves, J. Fantuch, S. Kahwage, and F. de Assis Alencar, “A cluster of polyneuropathy and Wernicke-Korsakoff syndrome in a bariatric unit,” Obesity Surgery, vol. 12, no. 3, pp. 328–334, 2002.
[18] D. Cerutti, P. Guilpain, A. Schiffmann et al., “Serious clinical manifestations of vitamin deficiency after a “sleeve” gastrectomy: Role of psychogenic anorexia,” La Revue de Médecine Interne, vol. 35, no. 9, pp. 609–612, 2014.
[19] N. R. Fuller, N. S. Lau, G. Denyer, and I. D. Caterson, “An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY,” Clinical Obesity, vol. 3, no. 6, pp. 172–179, 2013.